Therapy News and Research

RSS

Theramine may reduce chronic low back pain

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the company's proprietary medical food Theramine.

11 Jun 2012

Hospira releases enhancement to TheraDoc clinical surveillance system

Hospira, the world's leading provider of injectable drugs and infusion technologies, today released an important enhancement to its TheraDoc clinical surveillance system designed to support hospital antimicrobial stewardship efforts, with the goal of helping to improve patient outcomes, reduce antimicrobial resistant infections and reduce costs.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cyberonics, Imricor enter agreement to develop MRI compatible leads for VNS Therapy System

Cyberonics, Inc. today announced that it has entered into an exclusive technology license agreement with Imricor Medical Systems, Inc. to develop Magnetic Resonance Imaging ("MRI") compatible leads for use with the VNS Therapy System (Vagus Nerve Stimulation).

11 Jun 2012

$27 million received to speed new treatments for disabling neurological disorder

The Johns Hopkins University School of Medicine has announced receipt of a five-year, $27 million gift earmarked to fast-track the development of therapies to treat tumors associated with neurofibromatosis type 1 (NF1), a common and often debilitating neurogenetic disorder that causes tumors called plexiform neurofibromas to grow on nerves anywhere in the body.

11 Jun 2012

Distinct cancer 'signatures' may help predict response to estrogen-lowering therapy

Decoding the DNA of patients with advanced breast cancer has allowed scientists to identify distinct cancer "signatures" that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.

11 Jun 2012

BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD

BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).

11 Jun 2012

Short sleep periods increase risk of stroke in normal-weight adults

Habitually sleeping less than six hours a night significantly increases the risk of stroke symptoms among middle-age to older adults who are of normal weight and at low risk for obstructive sleep apnea (OSA), according to a study of 5,666 people followed for up to three years.

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris.

11 Jun 2012

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

BCSI launches 5 new cyclotrons for isotope research and production

Best Cyclotron Systems is unveiling five new cyclotrons for isotope research and production at the Society of Nuclear Medicine (SNM) Annual Meeting on June 9-12 in Miami Beach, Florida.

11 Jun 2012

Study confirms linear association between JBA and future stroke rate

Researchers from the Imperial College Faculty of Medicine in London in the United Kingdom revealed that the presence and size of a juxtaluminal black (hypoechoic) area (JBA) on carotid ultrasound of asymptomatic carotid artery plaques can predict the occurrence of ipsilateral ischemic stroke.

11 Jun 2012

Researchers describe germ line functions of par-5 gene

Certain proteins, such as 14-3-3, conserve their basic functions of cell cycle control in diverse organisms, from worms to humans. In a study led by Juli-n Cer-n and Sim- Schwartz Jr, researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Research Institute of Vall d'Hebron (VHIR) respectively, have described germ line functions of par-5, which is one of the two 14-3-3 proteins existing in Caenorhabditis elegans, worms used as experimental model in genetic studies.

10 Jun 2012

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Therapy News and Research

Theramine may reduce chronic low back pain

Hospira releases enhancement to TheraDoc clinical surveillance system

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Cyberonics, Imricor enter agreement to develop MRI compatible leads for VNS Therapy System

$27 million received to speed new treatments for disabling neurological disorder

Distinct cancer 'signatures' may help predict response to estrogen-lowering therapy

BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD

Short sleep periods increase risk of stroke in normal-weight adults

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

BCSI launches 5 new cyclotrons for isotope research and production

Study confirms linear association between JBA and future stroke rate

Researchers describe germ line functions of par-5 gene

UF Proton Therapy Institute successfully treats first eye cancer patient

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News